News Sentiment

ETON sentiment intelligence

Eton Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 36.61 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-2.4% over one week, +15.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Eton Pharmaceuticals (ETON) Could Be 18% Undervalued As Valuation Questions Build

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction -2.4% Price reacting lower
Trend fit Trend active 15.9% over four weeks
Fair value 198.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 31
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
TradingView 8
Market source 8
Investing.com 5
simplywall.st 4
Stock Traders Daily 2
Ad-hoc-news.de 2
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 13
Deals and strategy 5
Regulatory and legal 1
Analyst action 1
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Stock Titan Direct company coverage

Eton Pharmaceuticals (ETON) CEO exercises options and RSUs, increasing stake

Eton Pharmaceuticals President & CEO Sean Brynjelsen increased his stake in the company by exercising employee stock options for 200,000 shares and converting 27,500 restricted stock units (RSUs) into common stock. Following these transactions, Brynjelsen directly holds 1,061,194

Tone
Positive 68/100
Event
Deals and strategy
Published
14 Jul 2026 21:20
Source
Stock Titan
Stock Titan Direct company coverage

Eton Pharmaceuticals (NASDAQ: ETON) CBO converts 10,000 RSUs into common shares

Eton Pharmaceuticals' Chief Business Officer, David Krempa, has exercised 10,000 Restricted Stock Units (RSUs), converting them into an equal number of common shares. These RSUs were part of a larger grant from July 12, 2022, vesting in equal annual installments. Following this t

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:14
Source
Stock Titan
Stock Traders Daily Direct company coverage

The Technical Signals Behind (ETON) That Institutions Follow

This article analyzes Eton Pharmaceuticals Inc. (NASDAQ: ETON) using AI-generated signals for institutional trading strategies. It highlights weak near-term sentiment but strong mid and long-term outlooks, identifying compelling upside potential with no resistance levels above th

Tone
Positive 70/100
Event
Market update
Published
13 Jul 2026 04:11
Source
Stock Traders Daily
Stock Titan Direct company coverage

Opaleye trims Eton Pharmaceuticals (ETON) stake with open-market sales

Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals (ETON), reported open-market sales of 126,685 shares of common stock between July 2 and July 7, 2026. The shares were sold at weighted average prices between $37 and $38, reducing Opaleye L.P.'s holdings to 2,680,000 sh

Tone
Negative 31/100
Event
Deals and strategy
Published
07 Jul 2026 22:39
Source
Stock Titan
Investing.com Direct company coverage

Eton Pharmaceuticals stock hits all-time high at 38.6 USD

Eton Pharmaceuticals (ETON) stock reached an all-time high of $38.60, reflecting a 164.21% total return over the past year and nearly 80% revenue growth in the last twelve months. Despite an InvestingPro tip suggesting the stock might be overbought, the platform's Fair Value anal

Tone
Positive 71/100
Event
Earnings
Published
07 Jul 2026 15:39
Source
Investing.com
Stock Traders Daily Direct company coverage

Precision Trading with Eton Pharmaceuticals Inc. (ETON) Risk Zones

This article analyzes Eton Pharmaceuticals Inc. (ETON) using AI models to provide precision trading strategies. It highlights strong sentiment across all horizons, suggesting an overweight bias, and details institutional trading strategies for long, breakout, and short positions

Tone
Positive 72/100
Event
Market update
Published
03 Jul 2026 01:40
Source
Stock Traders Daily
TradingView Direct company coverage

Enterprise value to revenue forward of Eton Pharmaceuticals, Inc. – NASDAQ:ETON

This article provides financial context for Eton Pharmaceuticals, Inc. (NASDAQ: ETON), focusing on its enterprise value to forward revenue. It is presented within the framework of TradingView's platform, offering an overview of the company's financial data. The content is concise

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 12:10
Source
TradingView
Stock Titan Direct company coverage

Eton Pharmaceuticals (ETON) CBO awarded 10,000 restricted stock units

Eton Pharmaceuticals' Chief Business Officer, David Krempa, was granted 10,000 restricted stock units (RSUs) as part of a compensation package. These RSUs will vest in four equal annual installments starting June 26, 2027, contingent on his continued employment. Following this gr

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 20:39
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Eton Pharmaceuticals Inc For: 30 June By Investing.com

Investing.com reported on a Form 4 filing for Eton Pharmaceuticals Inc. as of June 30th. The brief article, published in the stock market section, mentioned the company's stock symbol ETON and its recent performance. It primarily serves as a notice of the regulatory filing and in

Tone
Negative 42/100
Event
Regulatory and legal
Published
30 Jun 2026 20:39
Source
Investing.com Canada
Investing.com Direct company coverage

Eton Pharmaceuticals stock hits all-time high at 36.97 USD

Eton Pharmaceuticals (ETON) stock has reached an all-time high of $36.97, marking a 161.1% increase over the past year and pushing its market capitalization to $1.01 billion. This surge reflects strong investor confidence despite a mixed Q1 2026 earnings report where revenue beat

Tone
Positive 77/100
Event
Earnings
Published
30 Jun 2026 18:40
Source
Investing.com
TradingView Direct company coverage

Enterprise value to revenue forward of Eton Pharmaceuticals, Inc. – BOATS:ETON

This article focuses on the "Enterprise value to revenue forward" metric for Eton Pharmaceuticals, Inc. (ETON) listed on the Blue Ocean Alternative Trade System (BOATS). It provides a brief overview without detailed financial data or analysis. The content appears to be a stub or

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 12:11
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Eton Pharmaceuticals, Inc. – NASDAQ:ETON

This article provides the "Price to sales forward" metric for Eton Pharmaceuticals, Inc. (NASDAQ: ETON). It specifically highlights the period, value, and change percentages for this financial indicator, noting that the market was closed at the time of publication with no recent

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 03:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Eton Pharmaceuticals, Inc. – BOATS:ETON

The article focuses on the "Enterprise value to EBITDA forward" metric for Eton Pharmaceuticals, Inc. (ETON) on the Blue Ocean Alternative Trade System (BOATS). It presents a financial snapshot within the TradingView platform, indicating a market closed status with no recent trad

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 21:40
Source
TradingView
TradingView Direct company coverage

ETON Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Eton Pharmaceuticals, Inc. (ETON) stock for 2027, based on analyst opinions. It includes current stock performance metrics, financial data, and answers frequently asked questions regarding ETON's stock price, volatility, marke

Tone
Positive 70/100
Event
Analyst action
Published
26 Jun 2026 22:12
Source
TradingView
Stock Titan Direct company coverage

ETON (ETON) Form 144: Affiliate sales include 25,000-share disposals

Eton Pharmaceuticals (ETON) affiliate James R. Gruber filed a Form 144 revealing proposed and past sales of common stock, including three dispositions totaling 53,117 shares in June 2026. The filing also detailed various issuer-side equity transactions like stock option exercises

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:39
Source
Stock Titan
TradingView Direct company coverage

Eton Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ETON)

This article provides an overview of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) stock, including its current price, market capitalization, and historical performance. It details financial actuals and estimates for earnings and revenue, analyst price targets, and future earnings re

Tone
Positive 77/100
Event
Earnings
Published
26 Jun 2026 18:39
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 144 Eton Pharmaceuticals For: 25 June By Investing.com

This article from Investing.com announces the Form 144 filing for Eton Pharmaceuticals on June 25, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article itself is very brief, serving primarily as an announcement

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 09:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

ETON (NASDAQ: ETON) notice: Director proposes sale of 25,000 shares

A director at Eton Pharmaceuticals (NASDAQ: ETON) has filed a Form 144, indicating a proposed sale of 25,000 shares related to a stock option exercise on June 25, 2026. This filing also discloses previous sales by the same individual, James R. Gruber, including 25,000 shares on J

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:13
Source
Stock Titan
TradingKey Direct company coverage

Eton Pharmaceuticals Inc (ETON) Institutional Confidence

Eton Pharmaceuticals Inc (ETON) has an institutional shareholding score of 5.00, ranking 73rd in the Pharmaceuticals industry. The institutional shareholding proportion is 58.43%, a decrease of 4.32% quarter-over-quarter. James Simons is the largest institutional shareholder, hol

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 10:40
Source
TradingKey
Stock Titan Direct company coverage

Insider files to sell 25,000 shares via option exercise | ETON SEC Filing - Form 144

An insider at Eton Pharmaceuticals (ETON) has filed a Form 144 to sell 25,000 shares through a stock option exercise scheduled for June 23, 2026. The filing also disclosed a prior sale of 3,117 shares on June 2, 2026, which generated $84,041.00. This administrative notice pertain

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 20:39
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 Eton Pharmaceuticals For: 23 June By Investing.com

This article from Investing.com reports on the filing of Form 144 by Eton Pharmaceuticals on June 23. It includes the stock symbol ETON and its performance, showing a 2.35% increase. The piece is brief and simply states the form filing event.

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 10:42
Source
Investing.com Canada
www.marketscreener.com Direct company coverage

Eton Pharmaceuticals, Inc.(NasdaqGM:ETON) added to S&P Pharmaceuticals Select Industry Index

Eton Pharmaceuticals, Inc. (NasdaqGM: ETON) has been added to the S&P Pharmaceuticals Select Industry Index. This news comes amidst recent insider stock sales, with one individual selling shares worth $1,623,795 on June 17, and another selling shares worth $3,229,923 on May 28. T

Tone
Positive 67/100
Event
Market update
Published
22 Jun 2026 01:40
Source
www.marketscreener.com
Investing.com South Africa Direct company coverage

Eton Pharmaceuticals director Adams sells 50,000 shares for $1.62m By Investing.com

Jennifer McKie Adams, a director at Eton Pharmaceuticals (NASDAQ:ETON), sold 50,000 shares of the company’s common stock for approximately $1.62 million on June 17, 2026, after exercising employee stock options. This transaction follows a 138% surge in ETON stock over the past ye

Tone
Negative 39/100
Event
Market update
Published
18 Jun 2026 19:39
Source
Investing.com South Africa
Investing.com Direct company coverage

Eton Pharmaceuticals director Adams sells 50,000 shares for $1.62m

Jennifer McKie Adams, a director at Eton Pharmaceuticals, sold 50,000 shares of the company’s common stock for approximately $1.62 million on June 17, 2026. This sale followed Adams exercising employee stock options at a much lower price. The company recently reported mixed Q1 20

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 04:10
Source
Investing.com
TradingView Direct company coverage

Eton Pharmaceuticals Director Sold Shares Worth Over $1.6M

Jennifer Mckie Adams, a Director at Eton Pharmaceuticals, sold 50,000 shares of common stock on June 17, 2026, for a total of $1,623,795. The shares were sold in multiple trades at an average price of $32.4759 per share. Following this transaction, the director no longer directly

Tone
Negative 39/100
Event
Market update
Published
17 Jun 2026 21:09
Source
TradingView